KR20230096024A - B 및 t 림프구 약화인자 (btla) 조절제 및 이의 사용 방법 - Google Patents

B 및 t 림프구 약화인자 (btla) 조절제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20230096024A
KR20230096024A KR1020237017524A KR20237017524A KR20230096024A KR 20230096024 A KR20230096024 A KR 20230096024A KR 1020237017524 A KR1020237017524 A KR 1020237017524A KR 20237017524 A KR20237017524 A KR 20237017524A KR 20230096024 A KR20230096024 A KR 20230096024A
Authority
KR
South Korea
Prior art keywords
ser
val
thr
gly
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237017524A
Other languages
English (en)
Korean (ko)
Inventor
마틴 에드워드 달
스티븐 팜리
마릴린 케리
진 다 실바 코레이아
모레나 쇼
Original Assignee
아납티스바이오, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아납티스바이오, 아이엔씨. filed Critical 아납티스바이오, 아이엔씨.
Publication of KR20230096024A publication Critical patent/KR20230096024A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020237017524A 2020-10-23 2021-10-22 B 및 t 림프구 약화인자 (btla) 조절제 및 이의 사용 방법 Pending KR20230096024A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105067P 2020-10-23 2020-10-23
US63/105,067 2020-10-23
US202163192984P 2021-05-25 2021-05-25
US63/192,984 2021-05-25
PCT/US2021/056289 WO2022087441A2 (en) 2020-10-23 2021-10-22 B and t lymphocyte attenuator (btla) modulators and method of using same

Publications (1)

Publication Number Publication Date
KR20230096024A true KR20230096024A (ko) 2023-06-29

Family

ID=78695822

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017524A Pending KR20230096024A (ko) 2020-10-23 2021-10-22 B 및 t 림프구 약화인자 (btla) 조절제 및 이의 사용 방법

Country Status (9)

Country Link
US (1) US20230391872A1 (enExample)
EP (1) EP4232480A2 (enExample)
JP (1) JP2023546713A (enExample)
KR (1) KR20230096024A (enExample)
AU (1) AU2021365611A1 (enExample)
CA (1) CA3196493A1 (enExample)
IL (1) IL302135A (enExample)
MX (1) MX2023004633A (enExample)
WO (1) WO2022087441A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023259623A1 (en) * 2022-04-27 2024-11-21 First Tracks Biotherapeutics, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2007001459A2 (en) * 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
CA2769473A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
JOP20190261A1 (ar) * 2017-05-19 2019-11-05 Lilly Co Eli أجسام مضادة لعامل مساعد لـ btla واستخداماتها
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
CN114585416B (zh) * 2019-04-01 2025-01-17 莱克制药股份有限公司 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体
AU2023259623A1 (en) * 2022-04-27 2024-11-21 First Tracks Biotherapeutics, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same

Also Published As

Publication number Publication date
WO2022087441A3 (en) 2022-08-25
CA3196493A1 (en) 2022-04-28
JP2023546713A (ja) 2023-11-07
AU2021365611A9 (en) 2025-03-13
EP4232480A2 (en) 2023-08-30
AU2021365611A1 (en) 2023-06-08
US20230391872A1 (en) 2023-12-07
IL302135A (en) 2023-06-01
WO2022087441A2 (en) 2022-04-28
MX2023004633A (es) 2023-05-12

Similar Documents

Publication Publication Date Title
US12391761B2 (en) Antibodies directed against interleukin 36 receptor (IL-36R)
US20210040198A1 (en) Antibodies directed against interleukin-33 (il-33)
US20220235132A1 (en) Pd-1 agonist and method of using same
US20250282872A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
US20230391872A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
EA053216B1 (ru) Модуляторы в- и т-лимфоцитарных аттенюаторов (btla) и способ их применения
CN116685603A (zh) B和t淋巴细胞衰减因子（btla）调节剂及其使用方法
HK40093375A (en) B and t lymphocyte attenuator (btla) modulators and method of using same
HK40086847A (en) Antibodies directed against interleukin 36 receptor (il-36r)
EA050223B1 (ru) Агонист pd-1 и способ его применения
HK1250941B (en) Antibodies directed against interleukin 36 receptor (il-36r)
EA044134B1 (ru) Анти-trem2 антитела и способы их применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230523

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241015

Comment text: Request for Examination of Application